Journal Article
Research Support, Non-U.S. Gov't
Add like
Add dislike
Add to saved papers

Promotive effect of C/EBPepsilon overexpression on differentiation of human myelomonocytic leukemia cell line U-937.

BACKGROUND & OBJECTIVE: CCAAT-enhancer binding protein omega (C/EBPepsilon) is a kind of nuclear transcriptional factor expressed predominantly in myeloid cells, and may be a critical regulator of myeloid differentiation, which can activate the transcription of a subset of myeloid-specific genes. This study was to detect the cell-specific expression of C/EBPepsilon, and to investigate the effect of C/EBPepsilon overexpression on c-Myc expression, cell cycle distribution, and cell differentiation of human myelomonocytic leukemia cell line U-937.

METHODS: The expression of C/EBPepsilon in 5 hematopoietic cell lines (U-937, NB4, HL-60, K-562 and Jurkat T cell lines) was tested by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR). According to the RT-PCR results, human myelomonocytic leukemia cell line U-937 was selected and transfected with pcDNA3.1-C/EBPepsilon32 expression vector by electroperforation, and screened by G418 to yield positive clones which were termed U-937-C/EBPepsilon32. The expression of C/EBPepsilon and c-Myc in U937-C/EBPepsilon32 cells was detected by RT-PCR and Western blot; cell cycle and differentiation of U937-C/EBPepsilon32 cells was analyzed by flow cytometry.

RESULTS: C/EBPepsilon overexpression obviously increased the expression of CD11b (a cell surface marker of granulocyte maturity). The positive rate of CD11b was significantly higher in U-937-C/EBPepsilon32 cells than in U-937 and U-937-pcDNA3.1 cells(92.56% vs. 77.46% and 74.81%), while c-Myc expression and cell cycle had no changes.

CONCLUSION: C/EBPepsilon might be an essential transcriptional regulator for U-937 cells differentiating into granulocytes.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app